Novel foods derived from cell culture instead of animals reduce the environmental impact of diets, water and land use by 80%, report Finnish researchers. 

VIB and Flemish Minister of Economy and Innovation, Hilde Crevits, announce the appointment of Dr Christine Durinx as VIB’s co-managing director, alongside Dr Jérôme Van Biervliet. Dr Jo Bury, co-founder and co-managing director since VIB’s inception 25 years ago, is passing the torch to Durinx who is the former Executive Director of the SIB Swiss Institute of Bioinformatics.

The approval of Valneva’s Corona vaccine is delaying. The European Medicines Agency’s CHMP requested additional data.

Organ-on-chip disease model specialist Mimentas BV participates in a €325m funding to accelerate preclinical cancer R&D in the Netherlands.

The US Food & Drug Administration has given the green light for Phase III testing of Hansa Biopharma’s imlifidase in anti-GBM disease.

GlaxoSmithKline acquires California-based Sierra Oncology and a ready-for-approval product candidate for myelofibrosis.

A 3D tumour model developed by scientists enables drug screening in metastases

Vetter, a globally operating CDMO, won the 2022 CMO Leadership Awards in all six core categories – quality, expertise, compatibility, capabilities, reliability and service. Vetter also achieved Champion status in the areas of quality, expertise and compatibility. The award, now in its eleventh year, was given by the leading trade press publication, Life Science Leader.

Following phantastic AFM13 data at AACR, Affimed N.V. prices it public offering at $84.4m.

Swiss neurology specialist GeNeuro SA present first data linking silent COVID-19-induced inflammations to neuropsyciatric diseases.